This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barnes, C. J. Articles by Lee, M. Search for Related Content PubMed PubMed Citation Articles by Barnes, C. J. Articles by Lee, M.

Effect of Aspirin on Prostaglandin E₂ Formation and Transforming Growth Factor Expression in Human Rectal Mucosa from Individuals with a History of Adenomatous Polyps of the Colon¹

Departments of Medicine [C. J. B., R. L. H-M., K. V. S., M. L.] and Cellular and Structural Biology [W. E. H., I. L. C.], University of Texas Health Science Center, San Antonio, Texas 78284

Colorectal cancer is the second-most frequent cause of cancer mortality in the United States. Human epidemiology and laboratory studies indicate that aspirin may be an effective colorectal cancer chemopreventive agent. This study was designed to determine whether treatment with 81 mg of aspirin per day for 3 months would alter two putative surrogate end point biomarkers of chemoprevention of colorectal cancer [i.e., mucosal prostaglandin E₂ (PGE₂) formation and transforming growth factor (TGF-) expression] in normal-appearing rectal mucosa from individuals with a history of adenomatous polyps. Rectal biopsies were obtained by flexible sigmoidoscopy at three sequential time points: (a) after a 1-month placebo run-in period (baseline), (b) after 3 months of ingesting 81 mg of aspirin (as a single tablet) once per day, and (c) after 3 months of ingesting a placebo tablet once per day (washout period). Daily aspirin significantly suppressed PGE₂ formation, but this significant suppression was completely reversed when aspirin was withdrawn. The extent of TGF- staining in rectal crypts was also reduced significantly (P = 0.039) by daily aspirin. After a 3-month placebo-washout period, however, the mean extent of TGF- staining was not significantly different from either baseline or the aspirin time point. Thus, 81 mg of aspirin daily significantly reduced rectal mucosal PGE₂ formation and TGF- expression in patients with a history of adenomatous polyps. These putative surrogate end point biomarkers may be useful intermediate end points in future colorectal cancer chemoprevention trials.

This article has been cited by other articles:

				G. Kune Commentary: Aspirin and cancer prevention Int. J. Epidemiol., October 5, 2007; (2007) dym194v1. [Full Text] [PDF]

				J. M Herendeen and C. Lindley Use of NSAIDs for the Chemoprevention of Colorectal Cancer Ann. Pharmacother., November 1, 2003; 37(11): 1664 - 1674. [Abstract] [Full Text] [PDF]

				J. A. Baron, B. F. Cole, R. S. Sandler, R. W. Haile, D. Ahnen, R. Bresalier, G. McKeown-Eyssen, R. W. Summers, R. Rothstein, C. A. Burke, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas N. Engl. J. Med., March 6, 2003; 348(10): 891 - 899. [Abstract] [Full Text] [PDF]

				J.R. Paterson and J.R. Lawrence Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer QJM, August 1, 2001; 94(8): 445 - 448. [Abstract] [Full Text] [PDF]

				K. Krishnan, M. T. Ruffin, D. Normolle, I. Shureiqi, K. Burney, J. Bailey, M. Peters-Golden, C. L. Rock, C. R. Boland, and D. E. Brenner Colonic Mucosal Prostaglandin E2 and Cyclooxygenase Expression before and after Low Aspirin Doses in Subjects at High Risk or at Normal Risk for Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 447 - 453. [Abstract] [Full Text]